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Abstract 
Background: The number of cancer survivors in the U.S. has increased from 3 million in 
1971, when the National Cancer Act was enacted, to over 12 million today. Over 70% of 
children affected by cancer survive more than 10 years, and most are cured. Most cancer 
survivors are adults, with two-thirds of them 65 years of age or older and two-thirds alive at 
five years. The most common cancer diagnoses among survivors include breast, prostate and 
colorectal cancers. This review was conducted to better appreciate the challenges associated 
with cancer survivors and the opportunities healthcare providers have in making a difference 
for these patients.  
Methods: Comprehensive review of literature based on PubMed searches on topics related 
to cancer survivorship, and associated physical, cognitive, socio-economic, sexual/behavioral 
and legal issues. 
Results: At least 50% of cancer survivors suffer from late treatment-related side effects, 
often including physical, psychosocial, cognitive and sexual abnormalities, as well as concerns 
regarding recurrence and/or the development of new malignancies. Many are chronic in na-
ture and some are severe and even life-threatening. Survivors also face issues involving lack of 
appropriate health maintenance counseling, increased unemployment rate and workplace 
discrimination.  
Conclusions: Advances in the diagnosis and treatment of cancer will lead to more survivors 
and better quality of life. However, tools to recognize potentially serious long-lasting side 
effects of cancer therapy earlier in order to treat and/or prevent them must be developed. It 
is incumbent upon our health care delivery systems to make meeting these patients’ needs a 
priority. 
Key  words:  Cancer  survivorship, detection  of  treatment  complications,  side  effects  of  therapy, 
secondary malignancies, socioeconomic/legal/healthcare policy issues. 
Introduction 
Cancer remains a major public health problem. 
The American Cancer Society projected over 1.5 mil-
lion new cancer cases would be diagnosed in 2010, 
with an estimated over half a million deaths from this 
disease [1]. It is estimated that the aging of America 
will contribute to a 45% increase in cancer incidence 
by  2030  [2].  Cancer  continues  as  the  second  most 
common cause of death (22.8%) following heart dis-
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eases (26.6%) [3]. The comparison of new diagnoses 
and mortality from cancer in 1971, when the National 
Cancer  Act  was  enacted  as  a  U.S.  federal  law,  and 
2010  indicates  that  although  the  number  of  cancer 
diagnoses  increased,  the  mortality  proportion  over 
those years declined (Table 1). This accounts for the 
increase in cancer survivors from 3 million in 1971 to 
nearly 12 million in 2007 [4]. Of those, it is estimated 
that 328,652 are survivors of childhood cancer [5]. 
 
Table 1. Cancer in the U.S.
a 
  1971  2010 
New Diagnosis  563,000  1,529,560 
Deaths  335,000  569,490 
Percent Mortality  53  37 
Survivors (millions)  3  12 
aAmerican Cancer Society comparison. 
 
 
The  expected  survivorship  from  cancer  in  the 
U.S. is summarized in Table 2. Almost 80% of children 
and 60% of adult cancer patients are expected to sur-
vive at least five years from diagnosis and many of 
them  are,  in  fact,  cured  from  cancer.  As  expected, 
most cancer survivors are adults 65 years of age or 
older.  
 
Table 2. Survival Information from the National Cancer 
Institute and Centers for Disease Control and Prevention. 
* 79% of childhood cancer survivors will be living five years after 
diagnosis and nearly 75% will be living 10 years following diagno-
sis. 
* 64% of adults whose cancer is diagnosed today can expect to be 
alive in five years. 
* 61% of cancer survivors are age 65 and older. 
* An estimated one of every six persons over the age of 65 is a can-
cer survivor. 
* Breast cancer survivors make up the largest group of cancer sur-
vivors (22%) followed by prostate cancer survivors (17%) and col-
orectal cancer survivors (11%).  
 
 
The  most  common  diagnoses  include  breast, 
prostate  and  colorectal  cancers  [6].  Similar  trends 
have  been  reported  from  other  countries  but  with 
appreciable regional differences. In a study of three 
common and one less common cancers (breast, colo-
rectal,  lung  and  ovary)  in  Australia,  Canada,  Den-
mark, Norway, Sweden and the United Kingdom, the 
survival of patients improved between 1995 and 2007, 
though survival was consistently higher in Australia, 
Canada, Sweden, intermediate in Norway, and lower 
in  Denmark,  England,  Northern  Ireland  and  Wales 
[7]. The majority of cancer survivors have been treated 
with aggressive medical, radiation and surgical ther-
apies administered either at a time when a patient’s 
organs were still developing, leading to complications 
later in life, or when the patient was already suffering 
from  underlying  degenerative  processes  where  the 
side effects of therapy represent insult over injury. As 
a result, long-term follow-up of cancer survivors re-
veals significant concern for cancer recurrence or de-
velopment  of  a  new  primary  cancers,  as  well  as 
physical,  cognitive,  socioeconomic,  sexual  and  legal 
issues. This review highlights some of these problems 
and brings to the attention of healthcare institutions, 
medical providers, health policy makers and society 
in general the urgent need to address these issues.  
Chronic and Late-Effect Health Conditions 
in Adult Survivors of Childhood Cancer 
The treatment of childhood cancer has been as-
sociated  with  risk  for  developing  several  chronic 
conditions that appear later in life, including physical, 
psychological,  cognitive  abnormalities  -  some  of 
which are severe and debilitating. In addition, survi-
vors from childhood cancer are at risk for developing 
secondary malignancies [8]. 
The  frequency  and  severity  of 
post-cancer-treatment  chronic  conditions  have  been 
reviewed by Oeffinger et al. [9]. Among participants 
of  the  Childhood  Cancer  Survivor  Study  cohort, 
comparative data were reported on the experiences of 
10,397 survivors and of 3,034 siblings. A chronic con-
dition was more common among survivors than their 
siblings  (62.3%  vs.  36.8%,  respectively).  Chronic  se-
quela of treatments was frequently multiple. Among 
patients with three or more chronic conditions, they 
were  more  common  among  survivors  than  in  their 
siblings (23.8% vs. 5.4%, respectively). The cumulative 
incidence of chronic conditions increased with time; 
66.8% at 25 years and 73.4% at 30 years. 
The  severity  of  post-treatment  chronic  condi-
tions  varies  substantially,  but  could  be  severe  and 
even  life  threatening.  Serious  conditions  were  also 
more common among survivors than in their siblings 
(27.5%  vs.  5.2%)  and  were  usually  associated  with 
chemo-radiation  regimens  and/or  with  those  con-
taining Doxorubicin and alkylating agents. The rela-
tive risk of the five most common serious conditions 
were major joint replacement at 54.0; congestive heart 
failure at 15.1; secondary malignant neoplasm at 14.8; 
severe  cognitive  dysfunction  at  10.5;  and  coronary 
artery disease at 10.4. 
Cognitive  impairment  is  associated  with  brain 
irradiation  and  can  impact  academic  achievement. 
The  most  common  cognitive  late-effect  of  moder-Int. J. Med. Sci. 2012, 9 
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ate-to-high dose whole brain radiation is diminished 
intellectual  capacity  [10].  Central  nervous  system 
(CNS) and acute lymphoblastic leukemia (ALL) sur-
vivors  are  at  risk  for  educational  deficits  [11].  The 
Children’s Cancer Group investigated the impact of 
treatment on scholastic performance of 593 adult sur-
vivors of ALL in comparison with 409 sibling controls 
[11]. Survivors treated with 24 Gy of cranial irradia-
tion  were  more  likely  to  enter  special  education  or 
learning disability programs. Survivors were as likely 
to finish high school and enter college as controls, but 
those treated with 24 Gy or treated before the age of 
six years were less likely to enter college.  
Significant  psychosocial  distress  has  been  re-
ported in survivors of childhood sarcoma treated with 
combined modality therapy [13]. The majority, 77%, 
had  abnormalities  in  the  Brief  Symptom  Inventory 
test  that  demonstrates  severity  scores  for  nine  psy-
chiatric  symptoms.  Twelve  percent  of  patients  met 
diagnostic criteria for Post-traumatic Stress Disorder. 
Psychological distress usually consisted  of  intrusive 
thoughts,  avoidant  behaviors  and  health  well-being 
concerns.  
Adult Cancer Survivors: Cardiac and Pul-
monary Late-Effects 
The late cardiac and pulmonary effects of ther-
apy on cancer survivors have recently been reviewed 
[14].  The  estimated  aggregate  incidence  of  radia-
tion-induced cardiac disease is 10% - 30%, occurring 5 
to 10 years from treatment. Radiation pneumonitis is 
reported in 5% - 15% of lung cancer patients, with a 
smaller  percent  developing  progressive  pulmonary 
fibrosis. However, in patients with severe underlying 
chronic obstructive pulmonary disease before radia-
tion therapy or chemoradiation therapy the outcomes 
are substantially worse.  
Valdivieso et al. reported an increase in pulmo-
nary  and  infection  morbidity  during  induction 
chemoradiation  therapy,  including  mitomycin  C, 
etoposide and cisplatin, in 43 patients with stage IIIB 
non-small cell lung cancer compared to a group of 41 
stage IV non-small cell lung cancer patients receiving 
the same chemotherapy but without chest irradiation. 
The frequency of these complications was greater ac-
cording  to  the  pre-treatment  severity  of  underlying 
small airway disease measured by forced expiratory 
flow (FEF25-75). In the group who received chemora-
diation therapy, there were 14/24, 4/8 and 0/11 epi-
sodes of pneumonia in patients with severe, moderate 
or normal FEF25-75, respectively (p 0.005) [15]. Brooks 
et al. also reported on the increase in pulmonary tox-
icity  of  80  small  cell  lung  cancer  patients  receiving 
combined  chemoradiation  versus  chemotherapy 
alone for  limited disease (p 0.017). Bilateral pulmo-
nary  infiltrates  beyond  the  radiation  therapy  port 
were  found  in  28%  of  patients  compared  to  5%  in 
those receiving chemotherapy alone. Eight of 13 pa-
tients  died  from  pulmonary  complications  with  no 
clinical evidence of tumor in five. Pretreatment pul-
monary function tests (PFT) revealed a significantly 
lower forced vital capacity (FVC) (p 0.03) and forced 
expiratory volume in 1 second (FEV-1) (p 0.04) in pa-
tients with subsequent pulmonary complications [16]. 
Theuws reported results of pulmonary function 
evaluations of 69 breast cancer patients and 41 lym-
phoma  patients  before  and  after  radiation  therapy 
alone  or  combined  with  chemotherapy,  including 
combinations  of  mechlorethamine,  vincristine,  pro-
carbazine,  prednisone,  doxorubicin,  bleomycin,  vin-
blastine,  cyclophosphamide,  epidoxorubicin,  fluor-
ouracil, thiotepa, carboplatin and methotrexate. After 
an initial reduction in PFTs at 3 months, significant 
recovery  took  place  at  18  months  for  all  patients. 
Thereafter,  no  further  improvement  could  be  docu-
mented  [17].  Thus,  pretreatment  pulmonary  abnor-
malities have a significant impact on the pulmonary 
complications from radiation therapy as they could be 
mild and transient or more severe and long lasting. 
Because  of  the  increased  risk  associated  with 
cancer treatment administered at a young age, adult 
survivors of pediatric cancer who received mediasti-
nal  radiation  (most  commonly  patients  with  Hodg-
kin’s  disease)  have  a  reported  increase  in  the  inci-
dence  of  coronary  artery  disease,  fatal  myocardial 
infarction and other cardiac complications. Hodgkin’s 
disease patients receiving mediastinal radiation have 
up to a 7.2 higher risk for fatal cardiovascular events 
than age and sex matched general population controls 
[18-20]. 
Doxorubicin-induced  cardiomyopathy  is  the 
most  frequent  and  most  studied  chemothera-
py-induced  cardiotoxicity.  The  risk  of  developing 
cardiotoxicity is mainly related to the cumulative dose 
of doxorubicin (1% to 5% up to 550 mg/M2, 30% at 
600 mg/M2, and 50% at 1 g/M2 with individual vari-
ation) [21]. Other anthracyclines are also cardiotoxic. 
Cardiac  abnormalities  are  likely  to  be  observed  in 
survivors  from  childhood  cancer  and  in  adults  un-
dergoing long-term follow-up. A higher risk popula-
tion  is  described  as  those  in  the  extremes  of  age, 
higher  cumulative  dose,  mediastinal  radiation  and 
female  sex.  An  overall  9%  incidence  of  doxorubi-
cin-related  cardiac  abnormalities  in  asymptomatic 
survivors that required treatment and close follow-up 
has  been  reported  [22].  An  abnormality  of  systolic 
function (abnormal wall stress, hypertrophy, contrac-
tility) was reported in 65 (43%) of 151 patients. Int. J. Med. Sci. 2012, 9 
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The  cardiotoxicity  of  breast  cancer  therapy 
among  survivors  has  recently  been  reviewed  [23]. 
Patients  with  doxorubicin-induced  congestive  heart 
failure (CHF) had an 87% improvement with cardiac 
medications; combined treatment with β-blockers and 
ACE  inhibitors  seemed  superior  to  ACE  inhibitors 
alone  [24].  These  results  contrast  with  retrospective 
reviews that reported mortality rates of 43% to 59% in 
similar patients [25]. 
Epirubicin  appears  less  cardiotoxic  than  doxo-
rubicin at equimolar doses, due to a lower level of 
secondary alcohol metabolites produced from epiru-
bicin  [26].  Cumulative  epirubicin  doses  of  >950 
mg/m2 are associated with an exponential increase in 
CHF risk [27]. Little cardiotoxicity was observed with 
a cumulative epirubicin dose of 300 mg/m2 [28]. 
Dexrazone  is  the  sole  cardioprotective  agent 
proved  to  decrease  anthracycline-induced  cardio-
myopathy. However, some suggest that it may inter-
fere  with  anthracycline  chemotherapy  because  an-
thracyclines enhance DNA cleavage by topoisomerase 
II,  but  the  closed  ring  form  of  dexrazone  stabilizes 
DNA-topoisomerase II complexes [29]. 
Taxanes,  particularly  paclitaxel,  have  shown 
evidence  of  cardiotoxicity.  In  contrast  to  previous 
reports, a large database has shown that only 0.1% of 
patients have serious bradycardia and could not con-
firm that taxanes increased the frequency of ventric-
ular  tachycardia  or  myocardial  infarction  [30].  Tax-
anes interfere with the metabolism and excretion of 
anthracyclines  and  potentiate  anthracycline-induced 
cardiotoxicity,  especially  at  high  cumulative  an-
thracycline  doses.  When  combined  with  paclitaxel, 
the cumulative doxorubicin dose should not exceed 
360 mg/m2, and doxorubicin should be given before 
paclitaxel [31]. Combination treatments with epirubi-
cin and taxanes may be less cardiotoxic. A cumulative 
epirubicin  dose  limit  of  990  mg/m2 in  combination 
treatments with paclitaxel has been proposed [32]. 
Recently, interest regarding the potential cardiac 
toxicity of trastuzumab has developed. Trastuzumab 
is a humanized monoclonal antibody that binds to the 
extracellular portion of the receptor HER2, a product 
of  the  HER2/neu  gene.  Although  the  exact  mecha-
nism  of  cardiotoxicity  of  trastuzumab  is  unknown, 
HER2  is  required  for  cardiac  development.  Single 
agent  trastuzumab  is  toxic  to  rat  myocytes  in-vitro 
because  it  induces  activation  of  the  mitochondrial 
apoptosis pathway and the caspase cascade. Neuro-
regulin, a cardiac stress peptide, may have a role in 
this problem [33]. The cardiotoxicity of trastuzumab 
has been recognized when given in combination with 
doxorubicin  (A)  and  cyclophosphamide  (C).  The 
combination  produces  a  16%  incidence  of  NYHA 
(New York Heart Association) classes III and IV rela-
tive to 3% with AC alone. Trastuzumab-related car-
diac  dysfunction  differs  from  anthracycline-induced 
myocardial damage in that it rarely causes death, is 
not dose related, and, in most instances, is reversible 
with improvement in cardiac function when the drug 
is  discontinued  and/or  the  patient  is  treated  with 
cardiac medications. 
Detection and Monitoring for Cardiac Tox-
icity 
The present detection of cardiac abnormalities in 
asymptomatic patients is suboptimal. Left ventricular 
ejection  fraction  (LVEF)  is  the  most  widely  used 
measure in the monitoring of cardiac toxicity. Patients 
with  a  healthy  LVEF  might  experience  subclinical 
changes, such as diastolic dysfunction, therefore, un-
derestimating  possible  cardiac  damage.  Echocardi-
ography  and  multiple  gated  acquisition  (MUGA) 
scintigraphy are the gold standard to measure LVEF. 
Echocardiography,  however,  provides  more  infor-
mation about the structure and function of the heart, 
including  assessment  of  diastolic  dysfunction  and, 
thus,  offers  greater  potential  for  the  monitoring  of 
cardiac  function  during  and  after  cancer  treatment. 
Several biomarkers, such as troponins and natriuretic 
peptides,  have  shown  promising  results  and  they 
should  be  studied  prospectively  and  in  conjunction 
with echocardiography to detect subclinical signs of 
cardiac dysfunction [34]. 
There is growing evidence of the importance for 
measuring global cardiac strain by Doppler imaging 
technology to identify heart damage in asymptomatic 
patients and in patients where standard echocardio-
gram  is  normal.  Promising  results  using  this  tech-
nique have been reported in patients with silent cor-
onary ischemia, ventricular failure, wall motion ab-
normalities,  amyloidosis  [35-38]  and  cancer  chemo-
therapy [39]. Sawaya and coworkers reported a de-
crease in longitudinal strain measured by echocardi-
ography in 43 patients at 3 months predicted cardio-
toxicity of anthracycline and trastuzumab treatment 
(p = 0.01) before any other test measuring LVEF. In 
addition, troponin 1 also significantly predicted car-
diotoxicity at 6 months (p = 0.006) [40]. 
Subsequent Neoplasms in Cancer Survi-
vors 
One of the most serious complications of cancer 
and its therapy is the development of additional ma-
lignancies (Table 3). The reported incidence of second 
malignancies in cancer survivors varies considerably, 
but according to the NCI Surveillance, Epidemiology, Int. J. Med. Sci. 2012, 9 
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and  End  Results  (SEER)  Program,  they  account  for 
16% of all cancers [41]. The development of these ma-
lignancies can be attributed to a number of factors, 
including  prior  chemotherapy  and/or  radiation 
therapy, lifestyle choices, the genetics of the individ-
ual, environmental exposures and their interactions. 
Second cancers and beyond have been well described 
in  survivors  of  childhood  and  adult-onset  cancers, 
particularly  in  patients  with  Hodgkin’s  disease,  as 
well as in patients with a history of prior cancer of the 
breast, prostate, testis, lung and cervix [42]. In general, 
the most commonly occurring second malignancies in 
adults are represented by the most common cancers 
overall  (i.e.,  breast,  prostate,  lung  and  colorectal), 
although leukemia has also been described [43-52]. 
Among children, Meadows et al reported on a 
long-term follow up of 14,358 childhood cancer sur-
vivors that were part of the Childhood Cancer Survi-
vor  Study  Cohort  [53].  At  30  years,  the  cumulative 
incidence  of  secondary  malignant  neoplasms  was 
9.3%,  and  that  of  non-melanoma  skin  cancer  was 
6.9%. By multivariate analysis,  greater risk was de-
scribed  for  those  receiving  radiation  therapy,  older 
age at diagnosis, female sex, family history of cancer 
and primary childhood cancer. Female survivors from 
Hodgkin’s disease or sarcoma and those who received 
radiation therapy were at increased risk. Compared to 
the general population, the largest risk excesses were 
found  for  breast  cancer,  bone  cancers  and  thyroid 
cancers.  
Over the years, greater emphasis has been placed 
on long-term surveillance of patients with Hodgkin’s 
disease. It has been recognized since the 1970’s that 
these patients are at greater risk for second malignan-
cies because of the type of chemotherapy, radiation 
therapy  or  combination  therapy  administered  to 
them. Among 18,862 5-year survivors from Hodgkin’s 
disease, Hodgson reported a 30-year cumulative risk 
for second malignancies of 18% and 26% for men and 
women respectively [54]. Metayer et al. described 195 
second cancers among 5,925 patients with Hodgkin’s 
disease  who  were  diagnosed  before  the  age  of  21 
years in the US, Europe and Canada. Eighty-one per-
cent of  second cancers  were solid  tumors from dif-
ferent  sites  that  occurred  at  an  average  of  16  years 
after  diagnosis  of  Hodgkin’s  disease.  Twenty-year 
survivors experienced significantly increased risks of 
cancers of the female breast, thyroid, digestive tract, 
lung, uterine cervix, bone and connective tissue [55]. 
A British study of 5,519 patients identified 322 second 
malignancies  among  Hodgkin’s  disease  patients 
treated between 1963 and 1993. They found a signifi-
cant increase in relative risk for gastrointestinal, lung, 
breast,  bone  and  soft  tissue  cancers  and  leukemia 
among younger patients at first treatment. Absolute 
excess risks and cumulative risks of solid tumors and 
leukemia were greater at older ages [56]. 
 
Table 3. Subsequent Malignancies among Cancer Survivors. 
Author  No. Patients  Diagnosis  New Cancers 
Ng & Travis [42]   1,319  Hodgkin’s Disease  189 (14.3%) 
Hodgson, et al. [54]   18,862  Hodgkin ’s disease  Men (18%) 
Women (26%) 
Metayer, et al. [55]   5,925  Hodgkin’s Disease  195 (3.2%) 
Swerdlow, et al. [56]   5,519  Hodgkin’s Disease  322 (5.8%) 
Okines [48]   3,764  Malignant Lymphoma  68 (1.9%) 
Heyne, et al. [59]   47  Small Cell Lung Cancer  14 (30%) 
van der Gaast, et al. [45]   81  Small Cell lung cancer  5 (6.1%) 
Takigawa, et al. [47]   90  Stage III Non-Small Cell Lung Cancer  7 (7.8%) 
4/19 (21%) long-term Survivors 
Raymond & Hogue [46]   332,014  Breast Cancer  40,068 (12%) 
Kirova, et al. [50]   16,705  Breast Cancer  709 (4.2%) 
Gianni, et al. [51]   1,035  Breast Cancer  55 (5.3%) 
Travis, et al. [43]   40,576  Testicular cancer  2,285 (5.6%) 
Stava, et al. [44]   968  Malignant Melanoma  111 (11.4%) 
Fernebro, et al. [49]   818  Soft Tissue Sarcoma  113 (13.8%) 
Chaturvedi, et al. [52]   85,109  Squamous Cell Ca. Cervix  10,559 (12.4%) 
10,280  Adenocarcinoma of Cervix  920 (8.9%) 
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Among  patients  with  Hodgkin’s  disease,  Ng 
reported  on  the  risk  of  developing  multiple  malig-
nancies in 1,319 survivors; 181 patients developed a 
second malignancy and 18 developed a third malig-
nancy [57]. The median time between the second and 
the third malignancy was 34 months. Similar experi-
ences  have  been  described  in  survivors  from  child-
hood cancer and in adult cancer survivors who de-
veloped up to five subsequent malignancies [46, 58]. 
In  a  data  base  of  consecutive  small  cell  lung 
cancer patients entering clinical trials at MD Ander-
son Cancer Center, Heyne et al. reported the devel-
opment of second cancers in fourteen of forty- seven 
(30%) survivors of two-years or more. Second cancers 
continued to develop during follow-up with an actu-
arial risk of 9.1%, 26.8% and 50% at 3, 5 and 8 years 
survival,  respectively.  The  most  common  second 
cancers were non-small cell lung, with others being 
bladder, esophagus, breast, bone, rectum and multi-
ple  primaries.  The  study  demonstrates  that  careful 
and  long-term  follow-up  of  small  cell  lung  cancer 
survivors reveals a very high incidence of second ma-
lignancies  [59].  The  development  of  second  malig-
nancies in small and non-small cell lung cancers has 
been reported to be lower by others, in the range of 6.1 
% to 21% [45,47]. 
Matesich reported that adjuvant chemotherapy 
for breast cancer is not associated with an increased 
risk  for  development  of  other  solid  tumors  beyond 
what is expected with normal aging. However, alkyl-
ating  agents,  such  as  cyclophosphamide  and  topoi-
somerase II inhibitors, are associated with two types 
of cytogenetically distinct leukemias. The risk of de-
veloping  leukemia,  however,  is  significantly  lower 
than the survival benefit from adjuvant chemothera-
py. Tamoxifen, on the other hand, is associated with a 
two- to threefold increase in the risk of developing 
endometrial  cancer  that  is  equivalent  to  approxi-
mately 80 excess cases per 10,000 treated women at 10 
years [60]. 
Quality of Life in Survivors  
Several  studies  have  addressed  quality  of  life 
issues in cancer survivors. Among young adults sur-
vivors of childhood cancer, Langeveld et al. reported 
that many survivors, except those with bone tumors, 
reported  being  in  good  health  and  that  most  were 
functioning well psychologically. It was also reported 
that  survivors  had  lower  rates  of  marriage  and 
parenthood [11]. The same authors reported that, in a 
sample of 400 long-term survivors of childhood can-
cer, predictors of a diminished quality life included 
female  gender,  unemployment,  severe  late  ef-
fects/health  problems  and  low  self-esteem.  Addi-
tionally, it was found that female survivors had more 
cancer-specific  concerns  than  males  survivors  [61]. 
Factors associated with serious psychological distress 
in long-term survivors of adult-onset cancer include 
age younger than 65 years, being unmarried or not 
living  with  a  partner,  having  less  than  high  school 
education, being uninsured, having co-morbidities, or 
having difficulty performing activities of daily living 
[62].  Among  adult  long-term  survivors  of  breast, 
prostate, colorectal cancer and lymphoma (5-10 years 
post-diagnosis),  older  respondents  expressed  better 
quality of life (p = 0.004), mental health (p < 0.001), 
but  worse  physical  health  (p  =  0.04)  [63].  Physical 
functioning  was  worse  among  those  reporting  low 
income (p = 0.02) and co-morbidities (p = 0.003). The 
evaluation of the impact of cancer score demonstrated 
that higher positive scores were associated with better 
mental health (p = 0.0004) and better overall quality of 
life (p = 0.005). 
Sexual  disturbances  are  common  among  adult 
survivors and they are often not addressed. Physical 
abnormalities and low hormone levels resulting from 
gonadal  injury  from  cancer  therapy  contribute  to 
lower  self-esteem,  depression,  less  desire  for  sexual 
activity and lower libido. This is particularly signifi-
cant  for  younger  women  undergoing  breast  cancer 
therapy  and  for  those  recovering  from  gynecologic 
malignancies [64-66].  
In breast cancer patients, ovarian abnormalities 
from chemotherapy are related to a number of factors 
including the direct damage of ovarian follicules, the 
ovarian function at the time chemotherapy begins and 
the  specific  chemotherapeutic  agent  employed  par-
ticularly alkylating agents such as cyclophosphamide 
[67].  Transient  or  permanent  amenorrhea  develops 
with  associated  symptoms  of  treatment  induced 
ovarian suppression such as hot flashes and osteopo-
rosis [68]. These abnormalities will also have a nega-
tive effect on fertility.  
Even  though  most  cancer  patients  suffer  from 
some degree of sexual dysfunction, patients with gy-
necologic malignancies, much like men with treated 
prostate  cancer,  develop  early  reduction  in  sexual 
activity that for some could be permanent [66, 69-71]. 
In addition, gynecologic patients have been found to 
have higher levels of depressive symptoms than pa-
tients with breast, gastrointestinal and urologic cancer 
survivors [72].  
Great progress has taken place in our knowledge 
of reproductive physiology to assure the existence of 
fertility preservation options for patients interested in 
having children after cancer therapy. These methods Int. J. Med. Sci. 2012, 9 
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include  reducing  the  impact  of  chemotherapy  on 
gonadal function, removing and preserving  ovarian 
tissue before starting chemotherapy, sperm banking 
and methods designed to produce mature oocytes or 
fertilized embryos for use in the future [67]. Cancer 
treatment choices and age have been considered in the 
development  of  an  algorithm  to  influence  fertility 
preservation [73].  
Sexual  dysfunction  abnormalities  are  frequent 
among cancer survivors regardless of gender and de-
serve close attention by care providers.  
Counseling Health Behaviors among Can-
cer Survivors 
It has been reported that cancer survivors receive 
less counseling by their primary care physicians on 
three important health behaviors: diet, exercise and 
smoking [74]. Utilizing the 2000 National Health In-
terview  Survey,  1,600  cancer  survivors  and  24,636 
adults  without  cancer  or  non-melanomatous  skin 
cancer history (controls) were studied. Among cancer 
survivors,  96%  were  diagnosed  after  the  age  of  18, 
there was a slight predominance of women (56% vs. 
44%)  and  the  majority  was  Caucasian  (82%).  Few 
survivors  reported  having  discussions  with  their 
health care providers related to diet (30% survivors 
vs. 23% controls; p < .0001), exercise (26% of survivors 
vs. 23% of controls; p < .005), or smoking cessation 
(42% of survivors vs. 41% of controls; p = .41). Survi-
vors reporting discussion with their physicians on all 
three health behaviors were even less (10% of survi-
vors and 9% of controls). Colorectal cancer survivors 
were less likely than controls of similar age range to 
report exercise recommendations (16% vs. 27%; p < 
.003) or smoking cessation (31% vs. 41%; p < .05), and 
cervical cancer survivors were more likely than con-
trols of similar age range to have discussions regard-
ing smoking (58% vs. 43%; p <.001). Thus, many pro-
viders  are  missing  the  opportunity  to  counsel  their 
cancer survivors on modification of important health 
behaviors. 
Survivors and Unemployment, Health In-
surance and Legal Issues 
Since the approval of the National Cancer Act of 
1971,  many  changes  have  occurred,  including  a 
greater understanding of cancer and its biology, better 
methods  for  early  detection,  improved  treatment 
outcomes and a larger number of cancer survivors in 
the U.S. The attitudes of patients and the public have 
also changed. Patients are less likely to be considered 
victims, their expectation of surviving is greater and 
so  are  their  prospects  with  regard  to  employment, 
health  insurance  and  preservation  of  their  human 
rights [75-76]. 
Many  survivors  are  ready  to  maintain  or  seek 
employment,  though  there  are  concerns  because  of 
employer  and  co-worker  misconceptions  regarding 
their ability to successfully return to work after ther-
apy. To address this issue, there are several federal 
and state laws in place to protect survivors from dis-
crimination. These include the Americans with Disa-
bility Act (ADA), Federal Rehabilitation Act, Family 
and  Medical  Leave  Act  (FMLA)  and  Employment 
Retirement  and  Income  Security  Act  (ERISA)  [75]. 
There is also increasing concern among patients and 
their  families  regarding  employer’s  discrimination 
based on genetic history. Several federal laws provide 
limited  protection  to  cancer  survivors:  the  Genetic 
Privacy Act, Genetic Privacy and Nondiscrimination 
Act, the ADA, and the Health Insurance Portability 
and Accountability Act. More than 30 states have ge-
netic non-discrimination laws. The levels of protection 
provided by these laws vary considerably [75]. 
Survivors report problems with job discrimina-
tion and obtaining health and life insurance [11]. A 
meta-analysis  and  meta-regression  study  of  20,366 
long-term cancer survivors, all with cancer diagnosis 
beyond the age of 18, has identified a higher percent 
of  unemployment  among  cancer  survivors  than  a 
healthy  control  population  of  157,603,  33.8%  vs. 
15.2%, respectively [77]. Specifically, unemployment 
was higher among survivors from breast cancer, gas-
trointestinal  cancers  and  cancers  of  the  female  re-
productive tract. Overall, survivors in the U.S. were 
1.5  times  more  likely  to  be  unemployed  than  their 
counterparts in Europe. Given the present poor status 
of our economy,  it is likely that this figure  will  in-
crease. 
Park et al. studied the prevalence and predictors 
of health insurance coverage in 12,358 5-year survi-
vors  of  childhood  cancer  and  3,553  sibling  controls 
participating in the Childhood Cancer Survivor Study 
[78].  Health  insurance  coverage  was  reported  by 
83.9%  of  adult  survivors  and  88.3%  of  siblings. 
Twenty-nine percent of survivors reported difficulty 
obtaining health insurance coverage, compared to 3% 
of  siblings  (p  <  .01).  Additionally,  survivors  were 
more likely to report exclusions or restrictions on their 
policies. Among survivors 18 years of age or older, 
factors associated with being uninsured included be-
ing diagnosed with cancer before the age of 15, male 
gender, lower level of attained education, income less 
than  $20,000,  marital  status,  smoking  status  and 
treatment that included cranial radiation. Other fac-
tors include prior diagnosis of leukemia, second ma-
lignancy and recurrence of original cancer.  Int. J. Med. Sci. 2012, 9 
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Clinical Research in Cancer Survivors 
There is significant interest in the understanding 
of the many problems cancer survivors face as a result 
of their disease process and or their treatment. The 
Children’s Oncology Group has pioneered the careful 
follow up of these patients resulting in carefully de-
veloped guidelines of care for survivors from child-
hood cancers and the study of some of their problems 
such  as  psychosocial,  cognitive  and  academic 
achievement,  and  developmental  issues.  The  guide-
lines of care for adults are more limited. Ongoing re-
search in adults focuses on symptom control, sexual 
dysfunction, obesity-nutrition-exercise, prevention of 
recurrence and of second malignancies. Examples of 
these studies by the SWOG cancer research coopera-
tive group, for instance, include: a. A feasibility study 
of  physical  activity  and  dietary  change  weight  loss 
intervention in breast and colorectal cancer survivors; 
b.  A  Phase  IIb  randomized  controlled  biomarker 
modulation  study  of  Vitamin  D  in  premenopausal 
women at high risk for breast cancer; c. A randomized 
placebo controlled trial of Omega-3-fatty acid for the 
control of Aromatase inhibitor induced musculoskel-
etal  pain  in  women  with  early  breast  cancer;  d.  A 
randomized  placebo-controlled  trial  of  Acetyl 
L-Carnitine  for  the  prevention  of  Taxane  induced 
neuropathy and; e. Phase  III trial of LHRH Analog 
administration during chemotherapy to reduce ovar-
ian  failure  following  chemotherapy  in  early  stage 
hormone-receptor  negative  breast  cancer.  What  is 
needed, however, are studies aimed at the early de-
tection and treatment of organ toxicity by the use of 
new  and  promising  technologies,  such  as  those  fo-
cusing in the cardiopulmonary system. 
Conclusion 
It is clear that surviving cancer today is associ-
ated with significant risk for cancer recurrence and/or 
the development of a new cancer plus physical, cog-
nitive, social, legal and economic problems. Although 
it  is  anticipated  that  modern  cancer  therapies  will 
alleviate some of these problems, they will not pre-
vent worsening of already existing degenerative pro-
cesses in adults, since it has been demonstrated that 
treatments hasten the development of future cardiac 
and  pulmonary  problems.  Nor  will  they  lessen  the 
socioeconomic issues experienced by cancer survivors 
either. The interactions between the individual’s ge-
netics, prior cancer therapy, environment and lifestyle 
choices  will  continue.  While  the  genetic  underpin-
nings of these interactions are unknown today, they 
represent a fruitful source of research in the future. 
Healthcare organizations, members of the med-
ical profession and advocacy groups need to heighten 
public awareness of these patients’ problems to assure 
that comprehensive programs are developed to attend 
to the many issues described here.  
Prospective sets of guidelines of care and sup-
portive  services  need  to  be  established  taking  into 
account the needs of children, adolescents and adults. 
A comprehensive multidisciplinary program or clinic 
that includes pediatric and adult hematologists and 
medical oncologists, primary care and internal medi-
cine physicians, as well as other medical and surgical 
specialists,  social  services,  geneticists,  legal  and  fi-
nancial counselors, would be necessary to better un-
derstand  and  optimally  assist  these  patients.  The 
amount of physical and staff resources necessary for 
these types of efforts are beyond what most commu-
nity settings or even academic cancer centers would 
be able to afford.  
A good alternative to comprehensive multidis-
ciplinary  survivor  clinics  is  the  expanded  oncology 
clinics,  provided  there  is  the  appropriate  physician 
and patient support systems to deliver cost-effective 
care under circumstances where most survivor pro-
grams  generate  limited  revenue.  Thus,  oncology 
trained  physician  extenders  and  nurse  clinicians 
could staff these clinics under the guidance of a phy-
sician  interested  in  survivor  issues.  Together,  they 
will implement survivorship guidelines into an over-
all survivor healthcare plan; they will refer patients to 
specialty clinics for specific problems requiring that 
type of expertise; and will work collaboratively with 
primary care physicians, or other home physicians, to 
assure  patients  get  the  appropriate  health  mainte-
nance programs at home. Social services support will 
be required in these clinics. An excellent level of ver-
bal  and  written  communication  among  healthcare 
providers will be essential for these programs to suc-
ceed.  
Cancer  survivors  need  all  members  of  the 
healthcare team to assist them in coping with many 
evolving challenges, and to live with dignity and re-
spect. We learn from them after they conquer cancer 
and, as providers, we join them at a new level of team 
approach that is ever-inspiring.  
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